IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Betenbaugh, et al.

Application Serial No.: 09/930,440

Group Art Unit: 1651

Filed: Augu

August 16, 2001

Examiner: To Be Assigned

Engineering Intracellular

Sialylation Pathways

Attny Docket No.: PF509P2

MENDMENT WITH STATEMENTS UNDER 37 C.F.R. § 1.825(a) AND (b)

Commissioner For Patents Washington, D.C. 20231

Sir:

In response to the Notice To Comply mailed on 01/09/2002 in connection with the above identified application, please enter the following amendments and consider the remarks below. Applicants submit herewith a Fee Transmittal, Second Substitute Sequence Listing (in paper and Computer Readable Form), and a copy of the Notice To Comply.

In the Sequence Listing:

Please delete the Substitute Sequence Listing submitted on December 4, 2001 (filed in response to the Notice To File Missing Parts mailed on 10/04/2001), and replace it with the Second Substitute Sequence Listing submitted herewith.

REMARKS

Applicants herewith submit a paper copy of a Second Substitute Sequence Listing (12 pages) and, a computer-readable diskette containing the Second Substitute Sequence Listing. The Second Substitute Sequence Listing (paper copy and computer readable form (CRF)) is submitted herewith to comply with the formalities under 37 C.F.R.. § 1.822 and/or § 1.823 noted on the Notice To Comply mailed on January 1, 2002, and the accompanying marked up "Raw Sequence Listing Error Report."